Seattle Genetics, Inc. and Genmab A/S have entered into an additional antibody-drug conjugate (ADC) collaboration. Under the new agreement, Genmab will pay an upfront fee of $11 million for exclusive ...

Seattle Genetics, Inc. and Laureate Pharma, Inc. have announced that they have entered into an agreement for manufacturing of Seattle Genetics' SGN-33 and SGN-70 humanized monoclonal antibody product ...

The Food and Drug Administration is imposing a clinical hold on several of Seattle Genetics’ early-stage studies involving an experimental cancer drug following the deaths of four people, Reuters ...

Merck has taken a $1bn equity stake in Seattle Genetics, with a total consideration of $4.5bn agreed for two of the biotech’s cancer drugs. The first drug covered in the deal, investigational antibody ...

Seattle Genetics, Inc. and Merck, known as MSD outside the United States and Canada, announced two new strategic oncology collaborations. The companies will globally develop and commercialize Seattle ...

COPENHAGEN, Sept 14 (Reuters) - Danish biotech company Genmab A/S will collaborate in cancer drug research with Seattle Genetics under a strategy to focus on strategic partnerships for drug ...

Seattle Genetics and partner Astellas have reported positive results from an early clinical trial of their antibody drug conjugate Padcev in combination with Merck & Co/MSD’s Keytruda in first-line ...

* Seattle Genetics announces global license agreement with immunomedics for sacituzumab govitecan (immu-132), a promising late-stage adc for solid tumors Sign up here. * Seattle Genetics Inc - planned ...

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ: SGEN) today announced dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SGN-CD48A for ...

Seattle Genetics, Inc. announced that Protein Design Labs, Inc. (PDL) has exercised an option for an exclusive license to an antigen target under the parties' antibody-drug conjugate (ADC) ...

An acquisition last year by a Pacific Northwest biotech company has paid off, in the form of a successful registration-directed breast cancer study. The company – which is based in the suburb of ...

Seattle Genetics (SGEN) came out with a quarterly loss of $1.13 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $0.73 per share a year ago. These figures are ...